Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.
Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatseas G, Timotheadou E, Zebekakis P, Efstratiou I, Gogas H, Vamvouka C, Chrisafi S, Stofas A, Pentheroudakis G, Koutras A, Galani E, Bafaloukos D, Fountzilas G. Mountzios G, et al. Among authors: timotheadou e. PLoS One. 2014 Mar 17;9(3):e91407. doi: 10.1371/journal.pone.0091407. eCollection 2014. PLoS One. 2014. PMID: 24637962 Free PMC article.
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.
Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou CH, Timotheadou E, Kalofonos CH, Kosmidis P, Adamou A, Papakostas P, Gogas H, Stathopoulos G, Razis E, Bafaloukos D, Skarlos D. Fountzilas G, et al. Among authors: timotheadou e. Ann Oncol. 2001 Nov;12(11):1545-51. doi: 10.1023/a:1013184301155. Ann Oncol. 2001. PMID: 11822753 Free article. Clinical Trial.
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, Dimopoulos AM. Fountzilas G, et al. Among authors: timotheadou e. Ann Oncol. 2005 Nov;16(11):1762-71. doi: 10.1093/annonc/mdi366. Epub 2005 Sep 7. Ann Oncol. 2005. PMID: 16148021 Free article. Clinical Trial.
Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.
Murray S, Timotheadou E, Linardou H, Vrettou AV, Kostopoulos I, Skrickova J, Papakostantinou C, Christodoulou C, Pectasides D, Samantas E, Papakostas P, Skarlos DV, Kosmidis P, Fountzilas G. Murray S, et al. Among authors: timotheadou e. Lung Cancer. 2006 May;52(2):225-33. doi: 10.1016/j.lungcan.2005.12.015. Epub 2006 Mar 29. Lung Cancer. 2006. PMID: 16567021
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
Pectasides D, Dafni U, Aravantinos G, Timotheadou E, Skarlos DV, Pavlidis N, Gaglia A, Kalofonos HP, Fountzilas G. Pectasides D, et al. Among authors: timotheadou e. Anticancer Res. 2007 Nov-Dec;27(6C):4411-7. Anticancer Res. 2007. PMID: 18214053 Free article. Clinical Trial.
67 results